Nuvectis Pharma (NVCT) Enterprise Value (2021 - 2026)

Nuvectis Pharma has disclosed Enterprise Value across 6 years of filings, most recently posting -$25.1 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$25.1 million, up 16.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.1 million (up 16.05% YoY), and the FY2025 annual result was -$31.6 million, changed N/A from the prior year.
• Enterprise Value came in at -$25.1 million for Q1 2026 at Nuvectis Pharma, up from -$31.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$13.6 million in Q2 2022 to a low of -$35.4 million in Q3 2025.
• The 5-year median for Enterprise Value is -$22.9 million (2022), against an average of -$22.8 million.
• Across the five-year window, Enterprise Value rose 26.36% in 2024 and sank 106.43% in 2025, its largest moves.
• Nuvectis Pharma's Enterprise Value stood at -$23.6 million in 2022, then grew by 6.51% to -$22.1 million in 2023, then rose by 22.31% to -$17.2 million in 2024, then plunged by 84.25% to -$31.6 million in 2025, then increased by 20.65% to -$25.1 million in 2026.
• The last three Enterprise Value figures came in at -$25.1 million (Q1 2026), -$31.6 million (Q4 2025), and -$35.4 million (Q3 2025), per Business Quant data.